Election Committee 2012
It was decided at the Artimplant Annual General Meeting on May 4, 2011 that the Election Committee would comprise the Chairman of the Board of Directors plus three members appointed by the three largest stockholders, according to voting power, as of September 30, 2011.
The composition of the Election Committee must be announced no later than six months prior to the Annual General Meeting.
Up to the 2012 Annual General Meeting the Election Committee shall comprise the following:
Lars Peterson, private stockholder and chairman of the Election Committee
John Arnold, private stockholder
Bo Kaunitz, private stockholder
Anders Cedronius, private stockholder and Chairman of the Board of Directors
Stockholders who wish to contact the Election Committee can do so by e-mail at firstname.lastname@example.org or by telephone on +46 (0)31-746 56 00.
For further information, please contact:
Kjell Thörnbring, CEO
Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production andmarketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and aremarketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.
Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.
This press release contains forward-looking statements as defined in theU.S.Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on November 3 at 9:00 AM (Swedish time).